e-Edition
Obituaries
Special Sections
Special Occasions
Contact
Subscribe
Paywall Login
Login to Comment
Register
December 11th, 2017
jobs
homes
Menu
Home
News
Sports
Business
Entertainment
Classifieds
Commentary
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
iShares Russell 2000 BuyWrite ETF
(NY:
IWMW
)
39.62
+0.02 (+0.05%)
Official Closing Price
Updated: 8:00 PM EST, Jan 8, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about iShares Russell 2000 BuyWrite ETF
< Previous
1
2
3
4
5
Next >
Hedge Fund Reportedly Prepares To Launch Board Fight At OraSure Technologies: Retail Investors Believe It’s Good News
↗
September 09, 2025
Altai Capital Management is one of the largest owners of OraSure and has increased its stake from 3% at the end of June to 5% in recent weeks, in an effort to press for board representation, Reuters...
Via
Stocktwits
Rapport Therapeutics Stock Rockets 204% Pre-Market To Head Toward All-Time Highs – Here’s What Happened
↗
September 08, 2025
Via
Stocktwits
Immunome Stock Rises After Craig-Hellum Initiates Coverage With $26 Price Target: Here’s Why The Analyst Sees An ‘Attractive Entry Point’
↗
September 05, 2025
Via
Stocktwits
Agios Pharma Stock Slumped 15% Today But Company Remains Top Pick For This Analyst – Find Out More
↗
September 04, 2025
While the FDA was originally expected to decide on the company’s application for Pyrukynd in treating thalassemia by September 7, its decision is now expected by December 7.
Via
Stocktwits
Novavax COVID-19 Vaccine Approved In Japan, Triggers Milestone Payment From Partner Takeda
↗
September 04, 2025
Via
Stocktwits
FDA Says No Advisory Committee Meeting Needed For Aquestive’s Oral Epinephrine Film
↗
September 04, 2025
Via
Stocktwits
Wave Life Sciences Tumbled 19% Today, But Not Everyone’s Disappointed – Find Out Why
↗
September 03, 2025
Via
Stocktwits
Tectonic Stock Soars Pre-market After Tuesday’s Sell-Off: Oppenheimer Is Hopeful About Company’s Lead Candidate
↗
September 03, 2025
Via
Stocktwits
Dynavax’s Experimental Shingles Vaccine Shows Positive Results In Study: Retail Expects Stock Rally To Continue Into Friday
↗
August 21, 2025
Via
Stocktwits
Zymeworks Stock Tanks Over 17% After Cancer Drug Candidate Update
↗
September 02, 2025
The company was testing the drug in an early-stage trial in patients with ovarian cancer and non-small cell lung cancer.
Via
Stocktwits
US FDA Withdraws Approval For Amylyx’s Neurodegenerative Disorder Drug, But BofA Hikes Price Target
↗
August 28, 2025
Bank of America analyst Tim Anderson raised the firm's price target on Amylyx to $14 from $10 while keeping a ‘Buy’ rating on the shares after the company reiterated earlier this week that it has a...
Via
Stocktwits
PTC Therapeutics Stock In The Spotlight After FDA Refuses Approval For Drug To Treat Neurodegenerative Disease, Analysts Are Divided
↗
August 19, 2025
Via
Stocktwits
Iovance Stock Rises 4% On Health Canada Approval For Cancer Immunotherapy: Retail Thinks ‘Patience Will Pay Off’
↗
August 19, 2025
Via
Stocktwits
Vanda Pharma Stock Rockets 9% After Federal Appeals Court Sets Aside FDA Action: Retail Expects Stock To Cross $5-Mark
↗
August 18, 2025
Via
Stocktwits
This Pharma Stock Shot Up 4% Pre-Market After FDA Approval For Drug, Retail’s Super Bullish But Believes ‘This Is A Marathon, Not A Sprint’
↗
August 18, 2025
Via
Stocktwits
Soleno Therapeutics Stock Slumps After Scorpion Capital Reveals Short Position: But Retail’s Not Pessimistic Yet
↗
August 15, 2025
Via
Stocktwits
This Aviation Stock Has Doubled In 2025, Surged Over 200% In 12 Months, And Is Trending On Friday – Do You Own It?
↗
August 15, 2025
Via
Stocktwits
Aquestive Therapeutics Stock Is Rising Pre-Market – Its $75M Funding Agreement Draws Divided Opinions From Retail
↗
August 14, 2025
Via
Stocktwits
Precigen Stock Shot Through The Roof On Friday Morning – Here’s Why
↗
August 15, 2025
The company stated that Papzimeos is now the first and only FDA-approved therapy for the treatment of adults with recurrent respiratory papillomatosis.
Via
Stocktwits
Hertz Expands Program Allowing Prolonged 3-Day Test Drives Before Vehicle Purchase To Over 100 Cities
↗
August 14, 2025
Consumers can test the vehicles for up to three days before purchasing at a low daily rate.
Via
Stocktwits
Schrödinger Discontinues Clinical Program After Two Patient Deaths
↗
August 14, 2025
Via
Stocktwits
Novavax CFO Says Sanofi To Cover Majority Of Future Nuvaxovid Study Costs, Retail Urges Partnership Diversification
↗
August 06, 2025
Via
Stocktwits
Ardelyx Stock Soars On Price Target Hikes After Upbeat Q2 Report: Retail Sees More Revisions Coming
↗
August 05, 2025
Via
Stocktwits
TG Therapeutics Stock Tumbles 15% After Disappointing Q2, But Company Reaffirms Confidence In Multiple Sclerosis Drug
↗
August 04, 2025
The company raised its Briumvi U.S. net product revenue target to $570 million to $575 million for the full year 2025, up from its previous guidance of $560 million.
Via
Stocktwits
Topics
Earnings
Novavax Announces Positive Preclinical Data From Bird Flu Vaccine: Retail Wonders When Will The Stock Be Fairly Valued
↗
July 24, 2025
Via
Stocktwits
Oscar Health Now Expects Loss From Operations Of $200M To $300M In 2025: Here’s What Retail Thinks About The Stock Price
↗
July 22, 2025
Via
Stocktwits
BioCryst Eyes Strengthening Pipeline After Upbeat Q2 Earnings: Retail Thinks Fair Valuation For Stock Is Double The Current Level
↗
August 04, 2025
CEO Jon Stonehouse stated during the company’s earnings call on Monday that the firm’s Netherton Syndrome and DME pipeline programs remain on track to have some data by the end of the year.
Via
Stocktwits
Topics
Artificial Intelligence
Earnings
CervoMed Dementia Drug Slows Disease Progression In Study: Retail Loads Up On The Stock
↗
July 28, 2025
The company is now poised to initiate late-stage trials for Neflamapimod.
Via
Stocktwits
This Pharma Stock Rose 200% On Monday Morning And Retail Says Valuation Could Rise To $5B: Here’s Why
↗
July 28, 2025
Sara Hurvitz, co-principal investigator for the trial, said that the data for both combination treatments in the trials are “potentially practice-changing.”
Via
Stocktwits
Topics
Death
Joby Aviation Stock Flies High On Expansion Of Marina Site, Retail Boards The Flight
↗
July 15, 2025
Once fully operational, the expanded Marina site is expected to be capable of producing up to 24 aircraft per year, or nearly one every other week.
Via
Stocktwits
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.